Poolbeg Pharma PLC
Poolbeg Pharma PLC
Your view on POLBF
Overview
What the company does, where it operates, and who runs it.
About Poolbeg Pharma PLC
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeremy Skillington
- Headquarters
- Queen Mary BioEnterprises Innovation Ctr, London, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeremy Skillington
- Headquarters
- Queen Mary BioEnterprises Innovation Ctr, London, GB
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.
It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Poolbeg Pharma PLC, and the rating behind it. POLBF last traded at $0.07; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Poolbeg Pharma PLC. Starting points for Poolbeg Pharma PLC: EPS -$0.0081, beta 2.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Poolbeg Pharma PLC. Poolbeg Pharma PLC does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Poolbeg Pharma PLC. Trailing twelve-month EPS for Poolbeg Pharma PLC stands at -$0.0081. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Poolbeg Pharma PLC. Poolbeg Pharma PLC has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Poolbeg Pharma PLC valued side by side against its closest peers. Poolbeg Pharma PLC is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Poolbeg Pharma PLC, and how their positions are changing. At a $46.6M market value, institutional positions materially move Poolbeg Pharma PLC's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Poolbeg Pharma PLC executives and directors. Shares of Poolbeg Pharma PLC have traded between $0.04 and $0.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Poolbeg Pharma PLC. Poolbeg Pharma PLC is a $46.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Poolbeg Pharma PLC. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Poolbeg Pharma PLC. Coverage tracks Poolbeg Pharma PLC within Biotechnology (Healthcare). Press releases and market coverage, newest first.